ArticleJournal of virology2023

Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease.

Nigel Bourne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.